 |
|
COMMENTS AND OPINIONS
HIV Eosinophilic Folliculitis in Uganda
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We read with interest the article by Toutous-Trellu et al1 about the beneficial effect of topical tacrolimus therapy for human immunodeficiency virus (HIV)-associated eosinophilic folliculitis (HIV-EF). The usefulness of such treatment has also been mentioned in other case reports.2-3 Based on the cases presented by Toutous-Trellu and colleagues, however, it is difficult to determine how efficient this treatment is and whether the lesions would have disappeared with the use of other topical medications in association with highly active antiretroviral therapy (HAART) or with HAART alone. The authors mention that HAART alone was insufficient to obtain a remission of HIV-EF, because the symptoms persisted during HAART in the period before the treatment with topical tacrolimus. From the description of the patients, however, it is unclear how long the skin lesions persisted during HAART. It is possible that even without topical tacrolimus therapy, all HIV-EF lesions would have disappeared after prolonged effective . . . [Full Text of this Article]
AUTHOR INFORMATION
Robert Colebunders, MD, PhD;
Barbara Castelnuovo, MD;
Helen Byakwaga, MD
RELATED ARTICLES
HIV Eosinophilic Folliculitis in Uganda—Reply
Laurence Toutous-Trellu and Vincent Piguet
Arch Dermatol. 2006;142(7):934-935.
EXTRACT
| FULL TEXT
Topical Tacrolimus for Effective Treatment of Eosinophilic Folliculitis Associated With Human Immunodeficiency Virus Infection
Laurence Toutous-Trellu, Shahnaz Abraham, Marc Pechère, Pierre Chavaz, Jan Lübbe, Véronique Schiffer, Bernard Hirschel, Jean-Hilaire Saurat, and Vincent Piguet
Arch Dermatol. 2005;141(10):1203-1208.
EXTRACT
| FULL TEXT
|
